Scopolamine intranasal - Nastech

Drug Profile

Scopolamine intranasal - Nastech

Latest Information Update: 09 Jun 2004

Price : $50

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Nausea and vomiting

Most Recent Events

  • 09 Jun 2004 Suspended - Preregistration for Emesis in USA (Intranasal)
  • 23 Mar 2000 The US FDA will not consider approving an NDA for Nastech's intranasal scopolamine formulation until more safety data is submitted
  • 23 Mar 2000 Preregistration for Emesis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top